Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005626 · ClinicalTrials.gov registry record · Phase 2
Phase II Trial With Correlative Laboratory Studies of Single Agent Irinotecan (Camptosar CPT-11)
A Phase 2 study, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT00005626 is a Phase 2 study that has completed, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 10 participants.
The verdict
NCT00005626, a Phase 2 study, has completed, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of irinotecan in treating patients who have newly diagnosed or relapsed non-Hodgkin's lymphoma or leukemia.
Interventions
- DRUG Irinotecan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 1998-02 |
| Est. Completion | 2003-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00005626
The ClinicalTrials.gov registry entry for NCT00005626 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Irinotecan is the first listed.
NCT00005626 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00005626 about?
NCT00005626 is a clinical study titled "Phase II Trial With Correlative Laboratory Studies of Single Agent Irinotecan (Camptosar CPT-11)". RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of irinotecan in treating patients who have newly diagnosed or relapsed non-Hodgkin's lymphoma or leukemia.
What is the current status of trial NCT00005626?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 1998-02. Estimated completion is 2003-11.
What interventions are being tested in trial NCT00005626?
The interventions under investigation include: Irinotecan (DRUG).
Who is sponsoring clinical trial NCT00005626?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.